ScreenerHero

RZLT Rezolute, Inc.

NAS · US · Healthcare · Biotechnology · rezolutebio.com
4.380USD+1.39%Mkt Cap: 423.64M $P/E: —

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead cli…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap423.64M USD
Enterprise Value310.97M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-74.41M USD
Revenue/Share—
Last Price4.380 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees58
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.28
PEG—
EV/EBITDA-3.82
EV/Revenue—
P/S—
P/B3.86
EPS (TTM)-0.75
EPS (Forward)-0.47
52W Range
1.07032% of range11.46
52W High11.46 USD
52W Low1.070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.90%
ROA-42.40%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.08M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-8.58%
Net Debt-106.87M USD
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity0.01
Current Ratio9.68
Quick Ratio9.44
Book Value/Sh1.12 USD
Cash/Share1.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 13, 2020
Splits
Last Split1:50
Split DateOct 13, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.800 USD
Upside (mean)+123.7%
Target Range6.000 USD – 15.00 USD
6.000+123.7% to mean15.00
# Analysts10
Ownership
Shares Out.96.72M
Float60.90M
Insiders9.74%
Institutions98.37%
Short Interest
Short Ratio12.3d
Short % Float26.24%
Short % Out.17.44%
Shares Short16.81M
Short (prev mo.)16.52M
Technical
SMA 504.486 (-2.4%)
SMA 2003.714 (+17.9%)
Beta0.54
S&P 52W Chg16.45%
Avg Vol (30d)1.73M
Avg Vol (10d)2.02M
Technical Indicators
RSI (14)53.1
MACD-0.0782
MACD Signal-0.1331
MACD Hist.+0.0549
BB Upper4.524 USD
BB Middle4.154 USD
BB Lower3.783 USD
BB Width17.85%
ATR (14)0.3336 USD
Vol Ratio (20d)0.95x